BioInformant, Your Global Leader in Stem Cell Industry Data’s Post

Exciting news was released today from Nucleus Biologics, an innovative provider of custom cell growth media, tools, and technologies. Congrats to the Nucleus Biologic's team on continuing to move the CGT field forward! Nucleus Biologics Launches NB-KUL™ DF: A DMSO-Free, Chemically-Defined Cryomedia Revolutionizing Cell and Gene Therapy Cryopreservation - https://lnkd.in/gmurbXpq Nucleus Biologics, a leading provider of cell culture and bioprocessing solutions for the cell and gene therapy (CGT) industry, has launched NB-KUL DF, a DMSO-free, chemically-defined cryomedia set to redefine cryopreservation standards. Designed for CGT manufacturers, NB-KUL DF matches DMSO-based media performance and outperforms other DMSO-free options in cell viability, recovery, and expansion. While DMSO is an effective cryoprotectant, its toxicity compromises cell viability, can cause patient issues, and requires complex wash steps, adding cost and variability. NB-KUL DF eliminates these issues, offering a DMSO-free solution that preserves cell integrity, eliminates the potential for patient side effects, and simplifies cryopreservation making it ideal for T cells, MSCs, and other sensitive cell types used in CGT. #celltherapy #genetherapy #research #ryopreservation David De Leonardis Brad Taylor Alyssa Master, PhD David Sheehan

PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c Agonist) - https://lnkd.in/gChdupbZ PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo; President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “FGF2 alternative peptide (FGFR1c agonist)”, which has equivalent function to recombinant FGF2 (Fibroblast Growth Factor 2, basic FGF (bFGF)). This product will be on the market at the beginning of October 2024. Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products face various quality challenges such as lot-to-lot variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that can address these challenges, while maintaining equivalent function to the conventional growth factors and cytokines on the market. Its peptides are completely chemically synthesized and animal component-free, enabling xeno-free and chemically defined cell culture media. #cellculture #regenerativemedicine #celltherapy

Global Experts in Temperature-Controlled Supply Chain Management for Critical Materials - https://lnkd.in/g29ibb8n Cryoport Systems is your strategic partner for comprehensive solutions that protect high-value biological materials throughout the supply chain. Its patented, state-of-the-art shipping systems, integrated global BioServices and biostorage capabilities, continuous cloud-based monitoring, and efficient local pickup and delivery services combined with tailored consulting services maximize the safety and quality of your life-saving therapies and critical materials. Risk Mitigation: Committed to your success From comprehensive traceability to our Veri-Clean® process, we are the only provider to requalify our shippers – every shipment, every time. Trust: Lean on its decades of experience Cryoport has supported 650+ clinical trials and have played a significant role in the commercialization of over a dozen products. Agility: Flexible solutions to meet your needs Cryoport's BioServices and biostorage solutions expand its flexible and scalable biomaterials management capabilities to every aspect of the supply chain for the discovery, development, and delivery of cell and gene therapies. Scalability: Comprehensive services for certainty in your supply chain It's continued growth and evolution of services add certainty to your supply chain with tailored solutions that fit your needs. Learn more at: https://lnkd.in/g29ibb8n #supplychain #celltherapies #genetherapies Natasha Frisch

Changing Dynamics in Umbilical Cord Blood and Tissue Banking - https://lnkd.in/e9hvvDbZ Cord blood is the blood that remains in the umbilical cord after the delivery of a newborn. It is a rich source of stem cells and immune system cells. During cord blood banking, these cells are isolated and cryopreserved for future use. The cells are collected from the two arteries and the vein which run along the length of the umbilical cord. The Wharton’s jelly is a gelatinous tissue that composes the umbilical cord, which also contains valuable therapeutic cells such as MSCs. Although cord blood storage emerged as a commercial service in the early 1990s, cord tissue storage didn’t emerge as a commercial service until 2008, when a Taiwanese company, HealthBanks Biotech Company Ltd., began offering the service making it the first company worldwide to do so. HealthBaby Biotech (Hong Kong) Co., Limited, a Hong Kong based company subsequently launched the service in 2009. Hong Kong-based CRYOLIFE company Ltd., added the service in 2009 as well. For placental banking, LifebankUSA Inc. initiated the service in the U.S. when it launched placental blood storage in 2006 and placental tissue storage in 2011. In September 2017, Americord Registry became the second U.S. cord blood bank to provide offering placental tissue banking. On April 17, 2023, the U.S. FDA also approved the world’s first expanded cord blood cell therapy (Omisirge). This was a landmark moment because numerous companies have been pursuing this goal for years. Omisirge is being developed by Gamida Cell Ltd. as an allogeneic cord blood cell therapy to speed up the recovery of white blood cells in cancer patients. Today, 80% of the global cord blood market is controlled by a handful of the world’s largest cord blood banking operators. Large market competitors include: Global Cord Blood Corporation (GCBC), Cord Blood Registry (owned by CooperSurgical), Polish Stem Cells Bank (PBKM)/ FamiCord Group, ViaCord, Cryo-Cell International, Cordlife Group Limited, Vcanbio Cell & Gene Engineering Corporation, LifeCell International Pvt.Ltd, CryoHoldco Biotech and Medipost. Read more at: https://lnkd.in/gNzdRxfZ #cordblood #cordbloodbanking #stemcell

StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment - https://lnkd.in/gNM5Zqhw StemCyte Inc. announced today that its Hematopoietic Progenitor Cell Cord Blood therapy (HPC Cord Blood) has officially obtained the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Long COVID-19 syndrome. StemCyte is one of the few cell therapy companies in the United States to receive the FDA-granted RMAT designation. Read more at: https://lnkd.in/gNM5Zqhw #rmat #fda #covid19

South Korea’s SK bioscience Completes Acquisition of Germany’s CDMO IDT Biologika - https://lnkd.in/g2mZWA9A SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the successful completion of its acquisition of a controlling stake in a German company, IDT Biologika, one of the top 10 global vaccine contract development manufacturing organizations (CDMO). Dr. Ulrich Valley, Co-CEO of IDT Biologika, said, “I am convinced that this milestone will contribute to future growth and to our vision of a leading CDMO. This global strategic cooperation is an important driver for our innovative strength, competitiveness and sustainable success, built on a foundation of trust and common goals. I am certain that we, SK bioscience and IDT Biologika, can achieve great things together by combining our competences and capabilities.” Jaeyong Ahn, President and CEO of SK bioscience, said, “With the successful completion of IDT Biologika acquisition, we are rapidly stabilizing management as SK bioscience and IDT Biologika now unite one family. The capabilities of the two companies are expected to generate significant synergies, and we will accelerate our global expansion.” Read more at: https://lnkd.in/g2mZWA9A #cdmo #acquisition #biotech

We are excited to share groundbreaking news from our innovative partner, AMSBIO. AMSBIO has introduced CellO-IF, an all-in-one reagent kit for immunofluorescent staining, designed to simplify the labeling of organoids and spheroids directly within hydrogels or extracellular matrices while preserving their delicate structures and cellular integrity. Immunofluorescence (IF) enables the detection and localization of antigens in a wide variety of tissue types. It offers higher sensitivity and signal amplification compared to immunohistochemistry. However, traditional IF methods involve multiple steps and are time-consuming. CellO-IF transforms this process by streamlining the workflow. With CellO-IF, there’s no need for harvesting, clearing, transferring, or centrifuging, which reduces sample loss and produces high-quality results in just a few hours. This simplified approach speeds up research while maintaining the natural 3D structure of samples, ensuring more accurate results. Offering superior antigen visualization, CellO-IF consistently delivers high-resolution images and is particularly effective for labeling samples with primary antibodies that previously failed with conventional methods. Available in two optimized formats for labeling both 3D and 2D samples, CellO-IF enhances target signal, providing clearer images and deeper insights for your research. Read more at: https://lnkd.in/gn7jRhVj Krystyna Joyce Bill Bradbury Alex Sim

When it comes to #bioprocess media, the company we always recommend is RoosterBio Inc. Their RoosterNourish™ is the industry's best-performing bioprocess media used for MSC expansion from R&D through clinical manufacturing. Years of formula and process optimization have increased productivity and eliminated media exchanges, which can drastically reduce your costs and expansion time by up to 60%. DID YOU KNOW that RoosterNourish media provides the same benefits to multiple cell types? •  Fibroblasts •  Immortalized MSCs • iPSC-derived MSCs • Autologous MSCs Learn more here: https://lnkd.in/eEE4BTuP #msc #stemcells #research #cellculture

Immunofluorescent Staining Within Hours, Not Days - https://lnkd.in/gn7jRhVj AMSBIO has launched CellO-IF – an all-in-one immunofluorescent staining reagent kit designed to accelerate the labelling organoids and spheroids directly in hydrogels or extracellular matrices, while preserving delicate structures and cellular integrity. Immunofluorescence (IF) allows detection and localization of antigens in diverse types of tissues in various cell preparations. The technique provides excellent sensitivity and amplification of signal by comparison to immunohistochemistry. However, traditional IF staining is a labor intensive, multi-step process. CellO-IF revolutionizes this by streamlining the procedure. Read more at: https://lnkd.in/gn7jRhVj #immunofluorescence #lifescience #stemcell

ARCH Venture Fund XIII Secures a Staggering $3 Billion to Support Early-Stage Biotech Companies - https://lnkd.in/gVCHia6p On September 26th, 2024, ARCH Venture Partners announced it had closed ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the launch and growth of early-stage biotech companies. This latest fund builds on ARCH’s longstanding goal of investing in transformative healthcare solutions, with a focus on advanced therapies, AI, and other cutting-edge solutions. Founded in 1986, ARCH Venture Partners has a history of supporting early-stage life sciences companies, particularly those focused on preventing, detecting, and curing diseases. Fund XIII’s investments to date include firms such as Arsenal Biosciences, Inc., Metsera, Mirador Therapeutics, and Xaira Therapeutics. ARCH’s also has a star-studded team of managing directors, including Robert Nelsen, Keith A. Crandall, Kristina Burow, Mark McDonnell, Steve Gillis, and Paul Berns. This collaborative leadership team works closely with pioneering scientists to commercialize groundbreaking technologies emerging from universities, national laboratories, and corporate research institutions. Their goal is to push the boundaries of life sciences R&D while driving impactful therapies to market. Read more at: https://lnkd.in/gVCHia6p